Gilead Sciences (GILD) Non Operating Interest Expenses (2009 - 2026)

Gilead Sciences (GILD) has reported Non Operating Interest Expenses for 18 consecutive years, with $247.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Interest Expenses fell 2.76% year-over-year to $247.0 million; the trailing twelve-month figure through Jun 2026 stood at $998.0 million (changed 0.3% YoY), and the FY2025 full-year result was $1.0 billion, up 4.81% from the prior year.
• Non Operating Interest Expenses climbed to $247.0 million in Q2 2026 per GILD's latest filing, from $240.0 million in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $260.0 million in Q1 2025 and bottomed at $226.0 million in Q4 2022.
• Historically, Non Operating Interest Expenses has averaged $242.7 million across 5 years, with a median of $241.0 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Non Operating Interest Expenses dropped 8.4% in 2022, then grew 11.5% in 2023.
• Over 5 years, Non Operating Interest Expenses stood at $226.0 million in 2022, then increased by 11.5% to $252.0 million in 2023, then declined by 1.19% to $249.0 million in 2024, then gained by 2.41% to $255.0 million in 2025, then declined by 3.14% to $247.0 million in 2026.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $247.0 million, $240.0 million, and $255.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.